These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 10668847)

  • 1. Increased bioavailability of oral melatonin after fluvoxamine coadministration.
    Härtter S; Grözinger M; Weigmann H; Röschke J; Hiemke C
    Clin Pharmacol Ther; 2000 Jan; 67(1):1-6. PubMed ID: 10668847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
    Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
    Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-- an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin.
    von Bahr C; Ursing C; Yasui N; Tybring G; Bertilsson L; Röjdmark S
    Eur J Clin Pharmacol; 2000 May; 56(2):123-7. PubMed ID: 10877005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-linear fluvoxamine disposition.
    Spigset O; Granberg K; Hägg S; Söderström E; Dahlqvist R
    Br J Clin Pharmacol; 1998 Mar; 45(3):257-63. PubMed ID: 9517369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
    Christensen M; Tybring G; Mihara K; Yasui-Furokori N; Carrillo JA; Ramos SI; Andersson K; Dahl ML; Bertilsson L
    Clin Pharmacol Ther; 2002 Mar; 71(3):141-52. PubMed ID: 11907488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics.
    Culm-Merdek KE; von Moltke LL; Harmatz JS; Greenblatt DJ
    Br J Clin Pharmacol; 2005 Nov; 60(5):486-93. PubMed ID: 16236038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men.
    Kusumoto M; Ueno K; Oda A; Takeda K; Mashimo K; Takaya K; Fujimura Y; Nishihori T; Tanaka K
    Clin Pharmacol Ther; 2001 Mar; 69(3):104-7. PubMed ID: 11240973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.
    Ozdemir V; Naranjo CA; Shulman RW; Herrmann N; Sellers EM; Reed K; Kalow W
    J Clin Psychopharmacol; 1998 Jun; 18(3):198-207. PubMed ID: 9617978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine.
    Lobo ED; Bergstrom RF; Reddy S; Quinlan T; Chappell J; Hong Q; Ring B; Knadler MP
    Clin Pharmacokinet; 2008; 47(3):191-202. PubMed ID: 18307373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L; Riesenman C; Lam YW
    Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.
    Yasui-Furukori N; Takahata T; Nakagami T; Yoshiya G; Inoue Y; Kaneko S; Tateishi T
    Br J Clin Pharmacol; 2004 Apr; 57(4):487-94. PubMed ID: 15025747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine.
    Isohanni MH; Neuvonen PJ; Olkkola KT
    Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):168-72. PubMed ID: 16918719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
    Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
    Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of fluvoxamine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects.
    Kadokura T; den Adel M; Krauwinkel WJ; Takeshige T; Nishida A
    Eur J Clin Pharmacol; 2008 Jul; 64(7):691-5. PubMed ID: 18438654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The major fluvoxamine metabolite in urine is formed by CYP2D6.
    Spigset O; Axelsson S; Norström A; Hägg S; Dahlqvist R
    Eur J Clin Pharmacol; 2001 Nov; 57(9):653-8. PubMed ID: 11791895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers.
    Saruwatari J; Yasui-Furukori N; Niioka T; Akamine Y; Takashima A; Kaneko S; Uno T
    J Clin Psychopharmacol; 2012 Apr; 32(2):195-9. PubMed ID: 22367658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans.
    Becquemont L; Ragueneau I; Le Bot MA; Riche C; Funck-Brentano C; Jaillon P
    Clin Pharmacol Ther; 1997 Jun; 61(6):619-27. PubMed ID: 9209244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone.
    Lamberg TS; Kivistö KT; Laitila J; Mårtensson K; Neuvonen PJ
    Eur J Clin Pharmacol; 1998; 54(9-10):761-6. PubMed ID: 9923581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidepressant-like effect of coadministration of sulpiride and fluvoxamine in mice.
    Ago Y; Harasawa T; Itoh S; Nakamura S; Baba A; Matsuda T
    Eur J Pharmacol; 2005 Sep; 520(1-3):86-90. PubMed ID: 16140294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction study between fluvoxamine and quazepam.
    Kanda H; Yasui-Furukori N; Fukasawa T; Aoshima T; Suzuki A; Otani K
    J Clin Pharmacol; 2003 Dec; 43(12):1392-7. PubMed ID: 14615476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.